Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 09 September 2025

Sec. Predictive Toxicology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1689499

Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

This article is a correction to:

  1. Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

    1. Read original article
Xinzhen CheXinzhen Che1Yong Zhu Yong Zhu2*
  • 1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
  • 2Shandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, Shandong, China

A Correction on
Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

by Che X and Zhu Y (2025). Front. Pharmacol. 16:1561937. doi: 10.3389/fphar.2025.1561937

The published article was incorrectly categorized as a Review article. The correct article type is “Original Research”. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ripretinib, sunitinib, adverse events, FAERS, GIST treatment

Citation: Che X and Zhu Y (2025) Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS). Front. Pharmacol. 16:1689499. doi: 10.3389/fphar.2025.1689499

Received: 20 August 2025; Accepted: 25 August 2025;
Published: 09 September 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Che and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yong Zhu, MTUxNjg4ODYzOTZAMTYzLmNvbQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.